JOSEPHINE M EGAN, M.D.
Osteopathic Medicine in Baltimore, MD
License number
Maryland D0040692
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
3001 S Hanover St Nia-Astra Unit FLOOR 5TH, Baltimore, MD 21225
Phone
(410) 558-8381
(410) 350-3979 (Fax)
(410) 350-3979 (Fax)
Personal information
See more information about JOSEPHINE M EGAN at radaris.comName
Address
Phone
1907 Brisbane St, Silver Spring, MD 20902
Organization information
See more information about JOSEPHINE M EGAN at bizstanding.comJosephine M Egan MD
251 Bayview Blvd #100, Baltimore, MD 21224
Categories:
Physicians & Surgeons
Phone:
(410) 558-8573 (Phone)
Professional information
See more information about JOSEPHINE M EGAN at trustoria.com
Josephine M Egan, Baltimore MD
Josephine M Egan, Baltimore MD
Specialties:
Endocrinologist
Address:
5600 Nathan Shock Dr, Baltimore, MD 21224
3001 S Hanover St, Brooklyn, MD 21225
3001 S Hanover St, Brooklyn, MD 21225
Education:
National University of Ireland - Doctor of Medicine
Baylor Clinic & Hospital - Fellowship - Pharmacology
Baylor Clinic & Hospital - Residency - Internal Medicine
University College Hospital Galway - NUI - Residency - Internal Medicine
University College Hospital Galway - NUI - Residency - Family Medicine
Baylor Clinic & Hospital - Fellowship - Pharmacology
Baylor Clinic & Hospital - Residency - Internal Medicine
University College Hospital Galway - NUI - Residency - Internal Medicine
University College Hospital Galway - NUI - Residency - Family Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Endocrinology and Metabolism (Internal Medicine)
Dr. Josephine M Egan, Baltimore MD - MD (Doctor of Medicine)
Dr. Josephine M Egan, Baltimore MD - MD (Doctor of Medicine)
Specialties:
Endocrinology, Diabetes & Metabolism, Endocrinology & Metabolism
Address:
3001 S Hanover St, Baltimore 21225
(410) 558-8381 (Phone), (410) 350-3979 (Fax)
251 Bayview Blvd SUITE 100, Baltimore 21224
(410) 558-8381 (Phone), (410) 350-3979 (Fax)
251 Bayview Blvd SUITE 100, Baltimore 21224
Certifications:
Diabetes, Metabolism & Endocrinology, 1989, Internal Medicine, 1987
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
3001 S Hanover St, Baltimore 21225
251 Bayview Blvd SUITE 100, Baltimore 21224
Medstar Harbor Hospital
3001 South Hanover St, Baltimore 21225
251 Bayview Blvd SUITE 100, Baltimore 21224
Medstar Harbor Hospital
3001 South Hanover St, Baltimore 21225
Education:
Medical School
University College of Cork / National University of Ireland
Baylor College Of Medicine
Regl Hosp
University College of Cork / National University of Ireland
Baylor College Of Medicine
Regl Hosp
Differentiation Of Non-Insulin Producing Cells Into Insulin Producing Cells By Glp-1 Or Exendin-4 And Uses Thereof
Differentiation Of Non-Insulin Producing Cells Into Insulin Producing Cells By Glp-1 Or Exendin-4 And Uses Thereof
US Patent:
2007004, Feb 22, 2007
Filed:
Apr 7, 2006
Appl. No.:
11/400715
Inventors:
Josephine Egan - Baltimore MD, US
Riccardo Perfetti - Washington DC, US
Antonino Passaniti - White Hall MD, US
Nigel Greig - Silver Spring MD, US
Harold Holloway - Middle River MD, US
Joel Habener - Newton Centre MA, US
Doris Stoffers - Moorestown NJ, US
Riccardo Perfetti - Washington DC, US
Antonino Passaniti - White Hall MD, US
Nigel Greig - Silver Spring MD, US
Harold Holloway - Middle River MD, US
Joel Habener - Newton Centre MA, US
Doris Stoffers - Moorestown NJ, US
International Classification:
A61K 35/39, C12N 5/08
US Classification:
424093700, 435366000, 435325000
Abstract:
The present invention relates to a population of insulin producing cells made by a process comprising contacting non-insulin producing cells with a growth factor selected from the group consisting of GLP-1 or Exendin-4, growth factors having amino acid sequences substantially homologous to GLP-1 or Exendin-4, and fragments thereof. The present invention also relates to methods of differentiating non-insulin producing cells into insulin producing cells and of enriching a population of cells for insulin-producing cells. The present invention also relates to methods of treating diabetes.
Differentiation Of Non-Insulin Producing Cells Into Insulin Producing Cells By Glp-1 Or Exendin-4 And Uses Thereof
Differentiation Of Non-Insulin Producing Cells Into Insulin Producing Cells By Glp-1 Or Exendin-4 And Uses Thereof
US Patent:
7056734, Jun 6, 2006
Filed:
Aug 10, 1999
Appl. No.:
09/762538
Inventors:
Josephine Egan - Baltimore MD, US
Riccardo Perfetti - Washington DC, US
Antonino Passaniti - White Hall MD, US
Nigel Greig - Silver Spring MD, US
Harold Holloway - Middle River MD, US
Joel Habener - Newton Centre MA, US
Doris Stoffers - Moorestown NJ, US
Riccardo Perfetti - Washington DC, US
Antonino Passaniti - White Hall MD, US
Nigel Greig - Silver Spring MD, US
Harold Holloway - Middle River MD, US
Joel Habener - Newton Centre MA, US
Doris Stoffers - Moorestown NJ, US
Assignee:
The United States of America as represented by the Department of Health and Human Services, NIH - Washington DC
International Classification:
C12N 5/00
US Classification:
435325, 530308
Abstract:
The present invention relates to a population of insulin producing cells made by a process comprising contacting non-insulin producing cells with a growth factor selected from the group consisting of GLP-1 or Exendin-4, growth factors having amino acid sequences substantially homologous to GLP-1 or Exendin-4, and fragmets thereof. The present invention also relates to methods of differentiating non-insulin producing cells into insulin producing cells and of enriching a population of cells for insulin-producing cells. The present invention also relates to methods of treating diabetes.
Glp-1 Exendin-4 Peptide Analogs And Uses Thereof
Glp-1 Exendin-4 Peptide Analogs And Uses Thereof
US Patent:
7576050, Aug 18, 2009
Filed:
Jul 30, 2002
Appl. No.:
10/485140
Inventors:
Nigel Greig - Phoenix MD, US
Josephine Egan - Baltimore MD, US
Maire Doyle - Baltimore MD, US
Harold Holloway - Middle River MD, US
Tracy Ann Perry - Baltimore MD, US
Josephine Egan - Baltimore MD, US
Maire Doyle - Baltimore MD, US
Harold Holloway - Middle River MD, US
Tracy Ann Perry - Baltimore MD, US
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
A61K 38/26, C07K 14/605
US Classification:
514 2, 514 12, 530308, 530324
Abstract:
The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects.
Uses Of Notch Receptors, Notch Ligands, And Notch Modulators In Methods Related To Metabolic Diseases
Uses Of Notch Receptors, Notch Ligands, And Notch Modulators In Methods Related To Metabolic Diseases
US Patent:
7888116, Feb 15, 2011
Filed:
Jul 22, 2005
Appl. No.:
11/658189
Inventors:
Josephine M. Egan - Baltimore MD, US
Máire E. Doyle - Gainesville FL, US
Máire E. Doyle - Gainesville FL, US
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
C12N 5/00
US Classification:
435325
Abstract:
Disclosed are methods for identifying and isolating a precursor cell. Also, disclosed are methods of increasing insulin synthesis from a pancreatic B-cell. Further, disclosed are methods of improving pancreatic B-cell function. Still further, disclosed are methods of preventing or delaying the onset of a metabolic disease, methods of treating or preventing a metabolic disease in a subject, and to compositions for treating or preventing a metabolic disease in a subject in need of such treatment or prevention.
Glp-1, Exendin-4, Peptide Analogs And Uses Thereof
Glp-1, Exendin-4, Peptide Analogs And Uses Thereof
US Patent:
8278272, Oct 2, 2012
Filed:
Dec 18, 2008
Appl. No.:
12/317042
Inventors:
Nigel Greig - Phoenix MD, US
Josephine Egan - Baltimore MD, US
Maire Doyle - Baltimore MD, US
Harold Holloway - Middle River MD, US
Tracy Ann Perry - Baltimore MD, US
Josephine Egan - Baltimore MD, US
Maire Doyle - Baltimore MD, US
Harold Holloway - Middle River MD, US
Tracy Ann Perry - Baltimore MD, US
Assignee:
The United States of America, as represented by the Secretary, Department of Health & Human Services - Washington DC
International Classification:
A61K 38/26, C07K 14/605
US Classification:
514 117, 514 177, 514 178, 514 179, 530308
Abstract:
The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects.
Taste Signaling In Gastrointestinal Cells
Taste Signaling In Gastrointestinal Cells
US Patent:
2005024, Nov 3, 2005
Filed:
Sep 24, 2004
Appl. No.:
10/949751
Inventors:
Josephine Egan - Baltimore MD, US
Stephen Gravine - Rutherford NJ, US
Robert Margolskee - Upper Montclair NJ, US
Richard McGregor - Rutherford NJ, US
Lenore Snyder - New York NY, US
Michael Theodorakis - Baltimore MD, US
Stephen Gravine - Rutherford NJ, US
Robert Margolskee - Upper Montclair NJ, US
Richard McGregor - Rutherford NJ, US
Lenore Snyder - New York NY, US
Michael Theodorakis - Baltimore MD, US
International Classification:
C12Q001/00
US Classification:
435004000
Abstract:
Disclosed are materials and methods relevant to taste transduction. Also disclosed are human gastrointestinal cells that comprise or are capable expressing endogenous taste signaling proteins. Also disclosed are human gastrointestinal cells that comprise or are capable of expressing endogenous taste signaling proteins as well as hormones, neurotransmitters or soluble mediators of the gastrointestinal tract that are involved in or affect metabolism, digestion and appetite. Also disclosed are the uses of these human cells or their membranes to study how compounds affect taste transduction and/or metabolism, digestion and appetite, including effects on satiety, emesis and diabetes.
Glp-1, Exendin-4, Peptide Analogs And Uses Thereof
Glp-1, Exendin-4, Peptide Analogs And Uses Thereof
US Patent:
2012032, Dec 27, 2012
Filed:
Aug 24, 2012
Appl. No.:
13/594313
Inventors:
Nigel Greig - Phoenix MD, US
Josephine Egan - Baltimore MD, US
Maire Doyle - Baltimore MD, US
Harold Holloway - Middle River MD, US
Tracy Ann Perry - Baltimore MD, US
Josephine Egan - Baltimore MD, US
Maire Doyle - Baltimore MD, US
Harold Holloway - Middle River MD, US
Tracy Ann Perry - Baltimore MD, US
Assignee:
The Gov. of the US, as represented by the Secretary, Dept. of Health & Human Services - Bethesda MD
International Classification:
A61K 38/26, A61P 25/00, A61P 25/28
US Classification:
514 117
Abstract:
The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating a subject with diabetes, comprising administering to the subject the polypeptide of the invention in an amount that has an insulinotropic effect. The invention also relates to methods of using GLP-1, exendin-4, and polypeptide analogues thereof for neuroprotective and neurotrophic effects.